Valvular Heart DiseasePREVASCNCT05892588
Prevalence Study of Cardiovascular Diseases in a Population ≥ 65 Years in Italy
An observational study of Valvular Heart Disease and Mitral Valve Disease, run by Azienda Ospedaliero-Universitaria Careggi at 1 site in Italy.
Trial summary
This registry is a large-scale epidemiological study (PREVASC) aimed at estimating the prevalence of symptomatic and asymptomatic valvular hear disease in men and women aged over 65 years randomly selected in Italy. Read more about this study
- Who is it for?
- Ages 65 years and olderHealthy volunteers can take part
- Conditions the study is for
- Valvular Heart Disease, Mitral Valve Disease, Aortic Valve Stenosis
- How many people
- 1,000 participants
- Where
- 1 siteItaly
- Study dates
- 1 Jun 2022to 1 Jul 2023
- How long will I take part?
- 1 Day
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 65 years and older
- All sexes
- Healthy volunteers accepted
- Older adult
Study population: Subject with > 65 years with no history of previous valvular heart disease living in villages with less than 3000 inhabitants.
Who may be able to join
- All subject ≥ 65 years with no history of previous valvular heart disease
Who cannot join
- Age <65 years
- Any acute disease
- Recent hospitalization (until 1 month).
Trial locations and contacts
1 site in 1 country.
Italy1 site, 1 recruiting
- Recruiting
AOUCareggi
Florence, 50134
Nazario Carrabba, phisician, 003933539482, carrabban@aou-caeggi.toscana.it
About this study
This registry is a large-scale epidemiological study (PREVASC) aimed at estimating the prevalence of symptomatic and asymptomatic valvular hear disease in men and women aged over 65 years randomly selected in Italy.
Read the detailed description
PREVASC is a cross-sectional, population-based study. Participating subjects are invited from the general population and underwent a physical examination and an electrocardiography and echocardiographic examination by a local cardiologist. A random sample of about 2000 subjects over 65 years will be considered for sampling. The sample size is determined on the basis of a priori criteria in order to estimate a prevalence of 3% [standard error (SE) ± 1.1] for VHD.
Both clinical and demographic information will be collected to better characterize the invited population. Written informed consent for the clinical examination will be asked.
Demographic variables, cardiovascular (CV) risk, clinical history, physical findings, and medications will be recorded in a Case Report Form (CRF) by physicians or trained nurses. Assessment of anthropometric measures, blood pressure, and heart rate will be performed according to MONICA recommendations. Overweight is defined as a body mass index (BMI) between 25 and 29.9 kg/m2. Obesity is defined as BMI ≥30 kg/m2. Symptoms and signs attributable to VHD will be evaluated and reported on the CRF by a dedicated expert physician in each site at the time of the physical examination.
Echocardiography Complete Colour Doppler echocardiography will be performed in peripheral centers using commercially available machines according to a pre-defined protocol. Echocardiograms will be recorded in standard DICOM format on digital.
The following parameters will be acquired:
- Linear measurements of cardiac chambers will be obtained from the two-dimensional (2D) parasternal long axis view or, when available, from the M-mode parasternal short axis recording according to the recommendations of the European American Society of Echocardiography and the European Association of Cardiovascular Imaging [].
- LV volumes will be obtained from the apical four-chamber view and the EF calculated by using the modified Simpson's rule method.
- Left ventricular mass will be calculated according to the Devereux formula.
- Left ventricular systolic function will be calculated using the formula for ejection fraction EF: EDV-ESV/EDV X100.
- Also left atrium area or volume will be measured by the 4-chamber view.
- Calcifications of the aortic valve and mitral apparatus will be quantified as light, moderate, or severe, according to a published approach. The bicuspid aortic valve will be searched for and recorded. Trans-aortic and trans-mitral gradients, as well as mitral, aortic, and tricuspid regurgitation, will be reported and quantified according to continuous wave Doppler and Color Doppler area of regurgitation or vena contracta (VC) width (light, moderate, severe), respectively. For quantitative measurement of mitral regurgitation and tricuspidal regurgitation PISA method will be used. For aortic regurgitation PHT will be adopted other than VC. The aortic valve area will be calculated using the continuity equation other than the planimetric area. Mitral valve area will be calculated using pressure half time (PHT) other than planimetric area. Pulmonary artery systolic pressure will be estimated according to standard method.
- Doppler-derived indexes of transmitral flow and pulmonary vein flow, and tissue Doppler imaging of the lateral mitral annulus (E/e') will be used to define diastolic LVD. Peak early diastolic filling wave (E) velocity, peak atrial diastolic filling wave (A) velocity, and deceleration time of the E wave (DTE) will be measured at the tips of the mitral leaflets. The DTE will be calculated as the time from E to the time when the descent of E intercepts the zero line. The duration of the transmitral A wave velocity will also be measured. The peak velocity of pulmonary venous (PV) systolic (S), and diastolic (D) flow, the peak velocity of PV backward flow at atrial contraction (PVa), and the PVa wave duration (PVa dur) will be measured with the sample volume placed in the right upper pulmonary vein in the four-chamber axis view. The difference between the transmitral A wave duration (Adur) and PVa dur will be derived as an indirect index of increased LV filling pressures, according to the standard method. Tissue Doppler will be used to calculate the E/e' ratio.
- All digital echocardiograms will be analyzed offline on a dedicated workstation by three independent observers, blind to clinical data, and reviewed by the same experienced reader. Measurements will be expressed as an average of three cycles in sinus rhythm and from three to five cycles in atrial fibrillation.
Cardiologists and nurses will be trained locally according to standardized methodologies. Before enrolment begins, all participating centers will be required to perform and send an echo test to the Core Lab to verify the appropriateness of the acquisition procedure.
- Conditions
- Valvular Heart Disease, Mitral Valve Disease, Aortic Valve Stenosis, Aortic Valve Insufficiency, Tricuspid Regurgitation
- Medical subject headings
- Heart Valve Diseases, Aortic Valve Stenosis, Aortic Valve Insufficiency, Tricuspid Valve Insufficiency
What is being measured
The primary outcome is the main question the study is designed to answer.
VALVOLAR HEART DISEASE PREVALENCE
The aim is to estimate the prevalence of symptomatic and asymptomatic valvolar heart disease in men and women aged over 65 years randomly selected in Italy: a complete colour-Doppler echocardiography will be performed in peripheral centres using commercially available machines according to a pre-defined protocol. Echocardiograms will be recorded with standard DICOM format on digital
Measured: at baseline
Secondary outcomes (2)
LEFT VENTRICOLAR DIMENSIONS AND FUNCTION
The aim is to estimate the prevalence of symptomatic and asymptomatic valvular heart disease in men and women aged over 65 years randomly selected in Italy: complete colour-Doppler echocardiography will be performed in peripheral centers using commercially available machines according to a pre-defined protocol. Echocardiograms will be recorded in standard DICOM format on digital
Measured: at baseline
BURDEN OF ATRIAL FIBRILLATION
The aim is to assess the burden of atrial fibrillation: a 12-lead electrocardiogram is performed to all patients enrolled
Measured: baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Jun 2023
- Study start1 Jun 2022
- Primary completion7 May 2023
- Study completion1 Jul 2023 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Valvular Heart DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Enrolment
- 1,000 participants (estimated)
- Target duration
- 1 Day
Sponsor and investigators
- Lead sponsor
- Azienda Ospedaliero-Universitaria Careggi
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05892588
- Sponsor's protocol ID
- PREVASC
- Acronym
- PREVASC
- Status last verified
- Jun 2023
- First submitted
- 25 May 2023
- Last updated
- 7 Jun 2023
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 7 Jun 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Prevalence Study of Cardiovascular Diseases in a Population ≥ 65 Years in Italy
- ClinicalTrials.gov ID
- NCT05892588
- Acronym / sponsor ID
- PREVASC / PREVASC
- Conditions
- Valvular Heart Disease, Mitral Valve Disease, Aortic Valve Stenosis, Aortic Valve Insufficiency, Tricuspid Regurgitation
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 1,000 participants (estimated)
- Lead sponsor
- Azienda Ospedaliero-Universitaria CareggiUniversity, hospital or other
- Study start
- 1 Jun 2022 (actual)
- Primary completion
- 7 May 2023 (actual)
- Study completion
- 1 Jul 2023 (estimated)
- First posted
- 7 Jun 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This registry is a large-scale epidemiological study (PREVASC) aimed at estimating the prevalence of symptomatic and asymptomatic valvular hear disease in men and women aged over 65 years randomly selected in Italy.
Detailed description
PREVASC is a cross-sectional, population-based study. Participating subjects are invited from the general population and underwent a physical examination and an electrocardiography and echocardiographic examination by a local cardiologist. A random sample of about 2000 subjects over 65 years will be considered for sampling. The sample size is determined on the basis of a priori criteria in order to estimate a prevalence of 3% [standard error (SE) ± 1.1] for VHD.
Both clinical and demographic information will be collected to better characterize the invited population. Written informed consent for the clinical examination will be asked.
Demographic variables, cardiovascular (CV) risk, clinical history, physical findings, and medications will be recorded in a Case Report Form (CRF) by physicians or trained nurses. Assessment of anthropometric measures, blood pressure, and heart rate will be performed according to MONICA recommendations. Overweight is defined as a body mass index (BMI) between 25 and 29.9 kg/m2. Obesity is defined as BMI ≥30 kg/m2. Symptoms and signs attributable to VHD will be evaluated and reported on the CRF by a dedicated expert physician in each site at the time of the physical examination.
Echocardiography Complete Colour Doppler echocardiography will be performed in peripheral centers using commercially available machines according to a pre-defined protocol. Echocardiograms will be recorded in standard DICOM format on digital.
The following parameters will be acquired:
- Linear measurements of cardiac chambers will be obtained from the two-dimensional (2D) parasternal long axis view or, when available, from the M-mode parasternal short axis recording according to the recommendations of the European American Society of Echocardiography and the European Association of Cardiovascular Imaging [].
- LV volumes will be obtained from the apical four-chamber view and the EF calculated by using the modified Simpson's rule method.
- Left ventricular mass will be calculated according to the Devereux formula.
- Left ventricular systolic function will be calculated using the formula for ejection fraction EF: EDV-ESV/EDV X100.
- Also left atrium area or volume will be measured by the 4-chamber view.
- Calcifications of the aortic valve and mitral apparatus will be quantified as light, moderate, or severe, according to a published approach. The bicuspid aortic valve will be searched for and recorded. Trans-aortic and trans-mitral gradients, as well as mitral, aortic, and tricuspid regurgitation, will be reported and quantified according to continuous wave Doppler and Color Doppler area of regurgitation or vena contracta (VC) width (light, moderate, severe), respectively. For quantitative measurement of mitral regurgitation and tricuspidal regurgitation PISA method will be used. For aortic regurgitation PHT will be adopted other than VC. The aortic valve area will be calculated using the continuity equation other than the planimetric area. Mitral valve area will be calculated using pressure half time (PHT) other than planimetric area. Pulmonary artery systolic pressure will be estimated according to standard method.
- Doppler-derived indexes of transmitral flow and pulmonary vein flow, and tissue Doppler imaging of the lateral mitral annulus (E/e') will be used to define diastolic LVD. Peak early diastolic filling wave (E) velocity, peak atrial diastolic filling wave (A) velocity, and deceleration time of the E wave (DTE) will be measured at the tips of the mitral leaflets. The DTE will be calculated as the time from E to the time when the descent of E intercepts the zero line. The duration of the transmitral A wave velocity will also be measured. The peak velocity of pulmonary venous (PV) systolic (S), and diastolic (D) flow, the peak velocity of PV backward flow at atrial contraction (PVa), and the PVa wave duration (PVa dur) will be measured with the sample volume placed in the right upper pulmonary vein in the four-chamber axis view. The difference between the transmitral A wave duration (Adur) and PVa dur will be derived as an indirect index of increased LV filling pressures, according to the standard method. Tissue Doppler will be used to calculate the E/e' ratio.
- All digital echocardiograms will be analyzed offline on a dedicated workstation by three independent observers, blind to clinical data, and reviewed by the same experienced reader. Measurements will be expressed as an average of three cycles in sinus rhythm and from three to five cycles in atrial fibrillation.
Cardiologists and nurses will be trained locally according to standardized methodologies. Before enrolment begins, all participating centers will be required to perform and send an echo test to the Core Lab to verify the appropriateness of the acquisition procedure.
Study design
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Target follow-up
- 1 Day
Who may qualify
- Ages
- 65 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Older adult
- Study population
- Subject with > 65 years with no history of previous valvular heart disease living in villages with less than 3000 inhabitants.
Key inclusion criteria (1 listed)
- All subject ≥ 65 years with no history of previous valvular heart disease
Key exclusion criteria (3 listed)
- Age <65 years
- Any acute disease
- Recent hospitalization (until 1 month).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
VALVOLAR HEART DISEASE PREVALENCE
Time frame: at baseline
The aim is to estimate the prevalence of symptomatic and asymptomatic valvolar heart disease in men and women aged over 65 years randomly selected in Italy: a complete colour-Doppler echocardiography will be performed in peripheral centres using commercially available machines according to a pre-defined protocol. Echocardiograms will be recorded with standard DICOM format on digital
2 secondary outcomes
LEFT VENTRICOLAR DIMENSIONS AND FUNCTION
Time frame: at baseline
BURDEN OF ATRIAL FIBRILLATION
Time frame: baseline
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Jun 2023.
Related trials for Valvular Heart Disease
Recruiting
Trial of the F2 Filter and Delivery System for Embolic Protection During TAVR
Aortic Stenosis Treated With TAVI, Aortic Diseases
Not yet recruiting
Human Experimental Models of Pain (HEMP)
Acute Pain
RecruitingObservational study
A Post-Market Assessment of the Safety and Performance of the TriClip™ System
Tricuspid Regurgitation (TR)
Active, not recruitingObservational study
Intravascular Lithotripsy in High Risk Calcified Iliac Anatomy for Transfemoral TAVR
Iliac Disease, Aortic Valve Stenosis
Not yet recruiting
NHLBI SESAME (SEptal Scoring Along Midline Endocardium) Multi-Center Prospective Study Using Improvised Off-Label Devices
Hypertrophic Cardiomyopathy, Left Ventricular Outflow Obstruction
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Valvular Heart Disease and Mitral Valve Disease, run by Azienda Ospedaliero-Universitaria Careggi at 1 site in Italy.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 7 Jun 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Nazario NC Carrabba, phisician (00393355939482, carrabban@aou-careggi.toscana.it), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
VALVOLAR HEART DISEASE PREVALENCE (time frame: at baseline). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Jun 2023.